Patients with Duchenne muscular dystrophy (DMD) are prescribed corticosteroid anti-inflammatory drugs as standard of care, but long-term use comes with significant adverse effects. For individuals ...
Dyne Therapeutics reports positive long-term data for DYNE-251 in Duchenne muscular dystrophy, aiming for U.S. accelerated approval in 2026. Dyne Therapeutics announced new long-term clinical data ...
BOULDER, Colo., March 10, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today presented at the 2026 MDA Clinical and Scientific ...
Please see Important Safety Information below and the full Prescribing Information. CONCORD, Mass., Aug. 25, 2025 /PRNewswire/ -- ITF Therapeutics LLC, the U.S. affiliate of Italfarmaco, today ...
SAN FRANCISCO -- Givinostat (Duvyzat) had a manageable long-term safety profile in Duchenne muscular dystrophy, data from an open-label extension study suggested. Most treatment-emergent adverse ...
RegenXBio Inc. ((RGNX)) announced an update on their ongoing clinical study. Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights ...
Comparable long-term effectiveness to classic corticosteroids, both prednisone (p=0.8587) and deflazacort (p=0.6544), based on time to loss of ambulation 80% fewer patients with vertebral fractures (8 ...
-Results in Performance of the Upper Limb (PUL v2.0) Continue to Show Slowing of Disease Progression in Later-Stage DMD Patients- -Improvements Seen in Multiple Cardiac Endpoints Demonstrating ...
LV end systolic volume, indexed (mL/m 2 )-2.4-5.1 LV end diastolic volume, indexed (mL/m 2)-5.7-10.0 Click to enlarge *Baseline is referred to as start of HOPE-2 study, changes in medians are shown; 3 ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results